These responses after immunization with a vaccine containing a similar prefusion-stabilized SARS-CoV-2 S protein as many current COVID-19 vaccines demonstrate that these narrow focused vaccines might already induce low levels of cross-reactive antibodies. Here, PROS1 is linked to COVID-19.